These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26735173)

  • 1. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
    Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
    Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
    Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
    Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner.
    Ramos H; Calheiros J; Almeida J; Barcherini V; Santos S; Carvalho ATP; Santos MMM; Saraiva L
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.
    Gomes S; Bosco B; Loureiro JB; Ramos H; Raimundo L; Soares J; Nazareth N; Barcherini V; Domingues L; Oliveira C; Bisio A; Piazza S; Bauer MR; Brás JP; Almeida MI; Gomes C; Reis F; Fersht AR; Inga A; Santos MMM; Saraiva L
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31405179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis.
    Loureiro JB; Ribeiro R; Nazareth N; Ferreira T; Lopes EA; Gama A; Machuqueiro M; Alves MG; Marabini L; Oliveira PA; Santos MMM; Saraiva L
    Pharmacol Res; 2022 Jan; 175():106026. PubMed ID: 34890775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.
    Zhang T; Wu K; Ding C; Sun K; Guan Z; Wang X; Hsieh JT; He D; Fan J
    Oncotarget; 2015 Nov; 6(35):37782-91. PubMed ID: 26462022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.
    Hiraki M; Hwang SY; Cao S; Ramadhar TR; Byun S; Yoon KW; Lee JH; Chu K; Gurkar AU; Kolev V; Zhang J; Namba T; Murphy ME; Newman DJ; Mandinova A; Clardy J; Lee SW
    Chem Biol; 2015 Sep; 22(9):1206-16. PubMed ID: 26320861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
    Wang W; Kim SH; El-Deiry WS
    Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11003-8. PubMed ID: 16835297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
    Bhonde MR; Hanski ML; Notter M; Gillissen BF; Daniel PT; Zeitz M; Hanski C
    Oncogene; 2006 Jan; 25(2):165-75. PubMed ID: 16170360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency and Selectivity Optimization of Tryptophanol-Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer.
    Barcherini V; Almeida J; Lopes EA; Wang M; Magalhães E Silva D; Mori M; Wang S; Saraiva L; Santos MMM
    ChemMedChem; 2021 Jan; 16(1):250-258. PubMed ID: 32737944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer.
    Xue Z; Sun PH; Zhu LM; Jiang SH; Qiao MM; Chi AL; Tu SP
    Oncol Rep; 2011 Apr; 25(4):1039-46. PubMed ID: 21279308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
    Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
    Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
    Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
    FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs.
    Sabatino MA; Previdi S; Broggini M
    Int J Cancer; 2007 Feb; 120(3):506-13. PubMed ID: 17096333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance.
    Loureiro JB; Raimundo L; Calheiros J; Carvalho C; Barcherini V; Lima NR; Gomes C; Almeida MI; Alves MG; Costa JL; Santos MMM; Saraiva L
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53.
    Sorriento D; Del Giudice C; Bertamino A; Ciccarelli M; Gomez-Monterrey I; Campiglia P; Novellino E; Illario M; Trimarco B; De Luca N; Iaccarino G
    Br J Cancer; 2015 Jan; 112(1):77-85. PubMed ID: 25422906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.